Literature DB >> 32662976

Tumor Necrosis Factor-α Trimer Disassembly and Inactivation via Peptide-Small Molecule Synergy.

James W Checco1, Geoffrey A Eddinger1, Nicholas J Rettko1, Alexander R Chartier1, Samuel H Gellman1.   

Abstract

Aberrant signaling by tumor necrosis factor-α (TNFα) is associated with inflammatory diseases that can be treated with engineered proteins that inhibit binding of this cytokine to cell-surface receptors. Despite these clinical successes, there is considerable interest in the development of smaller antagonists of TNFα-receptor interactions. We describe a new 29-residue α/β-peptide, a molecule that contains three β-amino acid residues and three α-aminoisobutryic acid (Aib) residues, that displays potent inhibition of TNFα binding to TNFα receptor 1 (TNFR1) and rescues cells from TNFα-induced death. The complement of nonproteinogenic residues renders this α/β-peptide highly resistant to proteolysis, relative to all-α analogues. The mechanism of inhibitory action of the new 29-mer involves disruption of the trimeric TNFα quaternary structure, which prevents productive binding to TNFα receptors. Unexpectedly, we discovered that peptide-induced trimer disruption can be promoted by structurally diverse small molecules, including a detergent commonly used during selection procedures. The discovery of this synergistic effect provides a new context for understanding previous reports on peptidic antagonists of TNFα-receptor interactions and suggests new avenues for future efforts to block signaling via proteins with an active form that is oligomeric, including other members of the TNFα family.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32662976      PMCID: PMC7654703          DOI: 10.1021/acschembio.0c00313

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  35 in total

1.  Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels.

Authors:  A Corti; G Fassina; F Marcucci; E Barbanti; G Cassani
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

2.  Engineered two-helix small proteins for molecular recognition.

Authors:  Jack M Webster; Rong Zhang; Sanjiv S Gambhir; Zhen Cheng; Faisal A Syud
Journal:  Chembiochem       Date:  2009-05-25       Impact factor: 3.164

3.  Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display.

Authors:  Daniel Steiner; Patrik Forrer; Andreas Plückthun
Journal:  J Mol Biol       Date:  2008-08-06       Impact factor: 5.469

Review 4.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

5.  Screening Nonionic Surfactants for Enhanced Biodegradation of Polycyclic Aromatic Hydrocarbons Remaining in Soil After Conventional Biological Treatment.

Authors:  Alden C Adrion; Jun Nakamura; Damian Shea; Michael D Aitken
Journal:  Environ Sci Technol       Date:  2016-03-11       Impact factor: 9.028

6.  Minimizing a binding domain from protein A.

Authors:  A C Braisted; J A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

7.  Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods.

Authors:  C Poiesi; A Albertini; S Ghielmi; G Cassani; A Corti
Journal:  Cytokine       Date:  1993-11       Impact factor: 3.861

8.  Structural Basis of Small-Molecule Aggregate Induced Inhibition of a Protein-Protein Interaction.

Authors:  Jonathan M Blevitt; Michael D Hack; Krystal L Herman; Paul F Jackson; Paul J Krawczuk; Alec D Lebsack; Annie X Liu; Taraneh Mirzadegan; Marina I Nelen; Aaron N Patrick; Stefan Steinbacher; Marcos E Milla; Kevin J Lumb
Journal:  J Med Chem       Date:  2017-03-16       Impact factor: 7.446

9.  Analysis of the molecular organization of recombinant human tumor necrosis factor (rTNF) in solution using ethylene glycolbis(succinimidylsuccinate) as the cross-linking reagent.

Authors:  K S Lam; P Scuderi; S E Salmon
Journal:  J Biol Response Mod       Date:  1988-06

10.  Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view.

Authors:  Shi Hu; Shuaiyi Liang; Huaizu Guo; Dapeng Zhang; Hui Li; Xiaoze Wang; Weili Yang; Weizhu Qian; Sheng Hou; Hao Wang; Yajun Guo; Zhiyong Lou
Journal:  J Biol Chem       Date:  2013-08-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.